| Dr Kaye Kip Owen, MD | |
|
5540 Raphael Dr, Edinburg, TX 78539-1407 | |
| (956) 362-6683 | |
| (956) 362-6809 |
| Full Name | Dr Kaye Kip Owen |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 36 Years |
| Location | 5540 Raphael Dr, Edinburg, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669477709 | NPI | - | NPPES |
| 5903260 | Other | AETNA | |
| 152741804 | Medicaid | TX | |
| DC6602 | Other | TX | MEDICARE RAILROAD |
| 106164100 | Other | DEPT. OF LABOR | |
| 0075KW | Other | TX | BCBS |
| 0900894 | Other | UNITED HEALTHCARE | |
| 123584 | Other | TX | CHIPS |
| 129930101 | Other | VALLEY HEALTH PLAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | H6491 (Texas) | Secondary |
| 207XX0005X | Orthopaedic Surgery - Sports Medicine | H6491 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital At Renaissance | Edinburg, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Renaissance Providers | 3476877879 | 19 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.
World renowned experts from Australia, the UK and the Ukraine are to speak at an international conference on autism, hosted at the University of Leicester by the organization jelibean.com, which provides help, advice and advocacy services to those on the autism spectrum, and those with AD/HD.
› Verified 5 days ago
| Entity Name | Renaissance Providers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336577477 PECOS PAC ID: 3476877879 Enrollment ID: O20150113000634 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.
World renowned experts from Australia, the UK and the Ukraine are to speak at an international conference on autism, hosted at the University of Leicester by the organization jelibean.com, which provides help, advice and advocacy services to those on the autism spectrum, and those with AD/HD.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kaye Kip Owen, MD Po Box 4624, Mcallen, TX 78502-4624 Ph: (956) 362-6683 | Dr Kaye Kip Owen, MD 5540 Raphael Dr, Edinburg, TX 78539-1407 Ph: (956) 362-6683 |
News Archive
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
A new gene-silencing technique that takes place in the nucleus of human cells, has been demonstrated by researchers at the University of California, San Diego (UCSD) School of Medicine and the VA San Diego Healthcare System.
World renowned experts from Australia, the UK and the Ukraine are to speak at an international conference on autism, hosted at the University of Leicester by the organization jelibean.com, which provides help, advice and advocacy services to those on the autism spectrum, and those with AD/HD.
› Verified 5 days ago
Dr. Manish Prabhakar Lambat, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2821 Michaelangelo Dr Ste 102, Edinburg, TX 78539 Phone: 956-362-8205 Fax: 956-362-8209 | |
Raul A Marquez, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2402 Cornerstone Blvd, Edinburg, TX 78539 Phone: 956-668-0060 Fax: 956-971-8809 | |
Dr. Eric Bradley Wilkinson, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 5540 Raphael Dr, Edinburg, TX 78539 Phone: 956-362-6683 Fax: 956-362-6823 | |
Dr. Patrick W Sander, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5540 Raphael Dr, Edinburg, TX 78539 Phone: 956-362-6683 Fax: 956-362-6818 | |
Dr. Jaime Villarreal Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5540 Raphael Dr, Edinburg, TX 78539 Phone: 956-362-6683 Fax: 956-362-6818 | |
Dr. Salvador Juventino Mendez, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5540 Raphael Dr, Edinburg, TX 78539 Phone: 956-362-6683 Fax: 956-362-6818 | |
Lionel Stacy Mitchell, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 3115 Center Pointe Dr, Edinburg, TX 78539 Phone: 956-618-5100 Fax: 956-618-9923 |